LLY

784.56

-0.86%↓

JNJ

150.85

-0.97%↓

NVO

74.09

-0.39%↓

ABBV

185.38

+0.09%↑

UNH

307.09

-0.49%↓

LLY

784.56

-0.86%↓

JNJ

150.85

-0.97%↓

NVO

74.09

-0.39%↓

ABBV

185.38

+0.09%↑

UNH

307.09

-0.49%↓

LLY

784.56

-0.86%↓

JNJ

150.85

-0.97%↓

NVO

74.09

-0.39%↓

ABBV

185.38

+0.09%↑

UNH

307.09

-0.49%↓

LLY

784.56

-0.86%↓

JNJ

150.85

-0.97%↓

NVO

74.09

-0.39%↓

ABBV

185.38

+0.09%↑

UNH

307.09

-0.49%↓

LLY

784.56

-0.86%↓

JNJ

150.85

-0.97%↓

NVO

74.09

-0.39%↓

ABBV

185.38

+0.09%↑

UNH

307.09

-0.49%↓

Search

AbCellera Biologics Inc

Chiusa

SettoreSettore sanitario

3.45 10.58

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

3.1

Massimo

3.48

Metriche Chiave

By Trading Economics

Entrata

-11M

-46M

Vendite

-815K

4.2M

EPS

-0.15

Margine di Profitto

-1,077.237

Dipendenti

596

EBITDA

16M

-40M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+121.52% upside

Dividendi

By Dow Jones

Utili prossimi

5 ago 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

328M

943M

Apertura precedente

-7.13

Chiusura precedente

3.45

Notizie sul Sentiment di mercato

By Acuity

50%

50%

157 / 381 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Very Strong Bearish Evidence

AbCellera Biologics Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

17 giu 2025, 14:44 UTC

Acquisizioni, Fusioni, Takeovers

Justice Department Orders Safran to Sell Assets to Proceed with Buy of Collins Aerospace Business

17 giu 2025, 23:43 UTC

Discorsi di Mercato

Nikkei May Fall Amid Uncertainty Over Israel-Iran Conflict -- Market Talk

17 giu 2025, 23:34 UTC

Discorsi di Mercato

Gold Steady, Underpinned by Ongoing Geopolitical Tensions -- Market Talk

17 giu 2025, 23:22 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

17 giu 2025, 23:22 UTC

Discorsi di Mercato

Global Energy Roundup: Market Talk

17 giu 2025, 23:22 UTC

Discorsi di Mercato

Meridian Energy Set to Draw Line Under 'Annus Horribilis' -- Market Talk

17 giu 2025, 23:17 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Tourism Holdings Likely to Seek Higher Offer -- Market Talk

17 giu 2025, 23:05 UTC

Discorsi di Mercato

Fletcher Building Could Signal Improved Shareholder Returns -- Market Talk

17 giu 2025, 23:05 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

17 giu 2025, 22:58 UTC

Discorsi di Mercato

Australian Treasurer Chalmers Expected to Outline Second-Term Reform Agenda -- Market Talk

17 giu 2025, 22:55 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

XRG Has a Good Argument for Regulatory Approval of Santos Deal -- Market Talk

17 giu 2025, 22:31 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Lifeway Foods CEO Not Surprised by Takeover Interest -- Market Talk

17 giu 2025, 22:14 UTC

I principali Market Mover

Bitdeer Technologies Group Shares Fall on Note Offering

17 giu 2025, 19:49 UTC

Discorsi di Mercato

Natural Gas Slow Down Gains -- Market Talk

17 giu 2025, 19:34 UTC

Discorsi di Mercato

Oil Rises On Israel-Iran Conflict Uncertainty -- Market Talk

17 giu 2025, 19:10 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

17 giu 2025, 19:10 UTC

Discorsi di Mercato

Dollar Strengthens, Treasury Yields Fall in Risk-Off Trade -- Market Talk

17 giu 2025, 18:41 UTC

Discorsi di Mercato

Slowdown in US Consumer Spending Expected -- Market Talk

17 giu 2025, 18:15 UTC

Discorsi di Mercato

Gold Inches Down as Profit-Taking Seen -- Market Talk

17 giu 2025, 17:44 UTC

Discorsi di Mercato

Analysts Forecast Record-High Ethanol Output -- Market Talk

17 giu 2025, 16:37 UTC

Discorsi di Mercato

A Buy-Canadian Policy Could Support Steel Producers -- Market Talk

17 giu 2025, 16:30 UTC

Discorsi di Mercato

Market Talk Roundup: Latest on U.S. Politics

17 giu 2025, 16:30 UTC

Discorsi di Mercato

Canada Seen Likely to Drop Digital-Services Tax -- Market Talk

17 giu 2025, 16:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

17 giu 2025, 16:15 UTC

Discorsi di Mercato

Base Metal Prices Mixed on Risk-Off Sentiment -- Market Talk

17 giu 2025, 16:12 UTC

Discorsi di Mercato

Gold Futures Fall as Safe-haven Demand Retreats -- Market Talk

17 giu 2025, 14:54 UTC

Discorsi di Mercato

Oil Rises on Continued Israel-Iran Conflict -- Market Talk

17 giu 2025, 14:47 UTC

Discorsi di Mercato

European Gas Climbs on Middle East Risks, EU Russian Ban Proposal -- Market Talk

17 giu 2025, 14:41 UTC

Discorsi di Mercato

Natural Gas Extends Climb -- Market Talk

17 giu 2025, 14:40 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

Confronto tra pari

Modifica del prezzo

AbCellera Biologics Inc Previsione

Obiettivo di Prezzo

By TipRanks

121.52% in crescita

Previsioni per 12 mesi

Media 7 USD  121.52%

Alto 10 USD

Basso 5 USD

Basato su 5 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per AbCellera Biologics Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

5 ratings

5

Acquista

0

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

1.99 / 2.635Supporto e resistenza

A breve termine

Very Strong Bearish Evidence

A termine intermedio

Very Strong Bearish Evidence

A lungo termine

Weak Bearish Evidence

Sentiment

By Acuity

157 / 381 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Neutral

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo AbCellera Biologics Inc

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.